Clinical Trial Detail

NCT ID NCT03390296
Title Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Avelumab + Azacitidine + PF-04518600

Azacitidine + PF-04518600

Avelumab + Utomilumab

Avelumab + Glasdegib

Gemtuzumab ozogamicin + Glasdegib

PF-04518600

Avelumab + PF-04518600

PF-04518600 + Utomilumab

Age Groups: adult senior

No variant requirements are available.